Cancer Focus Fund II

Cancer Focus Fund II has early commitments totaling more than $50 million towad our $250 million goal. Funding will be invested in more than 30 trials at this opportune time: capital is scarce, immunology is accelerating treatments and cures, and firms with first-in-class drugs are ready for clinical trials at our partner, MD Anderson Cancer Center.

Mission and Vision

Cancer Focus Fund II’s mission is to design, finance and enroll the most promising cancer treatments in clinical trials. Leveraging MD Anderson's unparalleled resources, we strive to deliver superior risk-adjusted returns to investors while delivering therapies that cure cancers or turn them into manageable diseases.

Why CFF II?

A generational opportunity
It’s about the timing. Venture capital funds are either babying their biotech assets or rushing them to public markets before they are ready to succeed. The fund can invest in overlooked immunotherapies that are ready to proceed through trials to market.

Quickening pace of oncology science
The invention of immunotherapies only 15 years ago has astonished scientists. More recent discoveries are opening paths to treat unresponsive cancers. Cancer Focus Fund has invested in novel first-in-class drugs, and has more candidates in the pipeline.

Upending risk-reward calculation 
Cancer Focus Fund’s process reduces risk at every step. Our Scientific Advisory Committee blind scores candidate drugs before meeting quarterly to select a few for potential testing. Meanwhile, rigorous due diligence ensures the firms have proven leadership and capital to emerge on the other side of clinical trials.